{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T14:06:55Z","timestamp":1774879615858,"version":"3.50.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s00120-026-02784-w","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T09:44:49Z","timestamp":1774431889000},"page":"429-437","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Medikament\u00f6se Therapie des benignen Prostatasyndroms","Pharmacotherapy of benign prostatic syndrome"],"prefix":"10.1007","volume":"65","author":[{"given":"P.","family":"Keller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Tamalunas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Atzler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Kidess","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leo","family":"Stadelmeier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Pyrgidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Hennenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian G.","family":"Stief","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Weinhold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"issue":"3","key":"2784_CR1","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/S0022-5347(17)49698-4","volume":"132","author":"SJ Berry","year":"1984","unstructured":"Berry\u00a0SJ et\u00a0al (1984) The development of human benign prostatic hyperplasia with age. J\u00a0Urol 132(3):474\u2013479","journal-title":"J Urol"},{"issue":"Suppl 1","key":"2784_CR2","first-page":"1","volume":"22","author":"C Vuichoud","year":"2015","unstructured":"Vuichoud\u00a0C, Loughlin\u00a0KR (2015) Benign prostatic hyperplasia: epidemiology, economics and evaluation. Can J Urol 22(Suppl 1):1\u20136","journal-title":"Can J Urol"},{"issue":"12","key":"2784_CR3","doi-asserted-by":"publisher","first-page":"4381","DOI":"10.1007\/s00345-021-03787-2","volume":"39","author":"A Miernik","year":"2021","unstructured":"Miernik\u00a0A et\u00a0al (2021) Real-world data and treatment patterns of patients with lower urinary tract symptoms due to benign prostatic hyperplasia in Germany: an observational study using health insurance claims data. World J Urol 39(12):4381\u20134388","journal-title":"World J Urol"},{"issue":"6","key":"2784_CR4","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.eururo.2020.12.019","volume":"79","author":"S Malde","year":"2021","unstructured":"Malde\u00a0S et\u00a0al (2021) A Systematic Review of Patients\u2019 Values, Preferences, and Expectations for the Diagnosis and Treatment of Male Lower Urinary Tract Symptoms. Eur Urol 79(6):796\u2013809","journal-title":"Eur Urol"},{"key":"2784_CR5","volume-title":"Management of Non-neurogenic Male LUTS. EAU Guidelines","author":"S Gravas","year":"2021","unstructured":"Gravas\u00a0S, Cornu\u00a0JN, Gacci\u00a0M, Gratzke\u00a0C, Herrmann\u00a0TRW, Mamoulakis\u00a0C, Rieken\u00a0M, Speakman\u00a0MJ, Tikkinen\u00a0KAO (2021) Management of Non-neurogenic Male LUTS. EAU Guidelines, Edn. presented at the EAU Annual Congress Milan 2021\u00a0edn. ISBN 978-94-92671-13\u20114.","edition":"Edn. presented"},{"key":"2784_CR6","unstructured":"Deutsche Gesellschaft f\u00fcr Urologie e.\u202fV. (ed) (2023) S2e-Leitlinie Diagnostik und Therapie des Benignen Prostatasyndroms (BPS), Langversion 5.0, 2023, AWMF- Registernummer: 043-034. https:\/\/www.urologenportal.de\/fachbesucher\/wirueberuns\/dgu\/leitlinien-der-deutschen-gesellschaft-fuer-urologie.html"},{"issue":"3","key":"2784_CR7","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s00120-009-1980-x","volume":"48","author":"R Berges","year":"2009","unstructured":"Berges\u00a0R (2009) Treatment of LUTS in BPS. When and when not to administer pills? Urologe A 48(3):257\u2013263","journal-title":"Urologe A"},{"key":"2784_CR8","volume-title":"Management of Non-neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO). EAU Guidelines","author":"JN Cornu","year":"2023","unstructured":"Cornu\u00a0JN, Gacci\u00a0M, Hashim\u00a0C, Herrmann\u00a0TRW, Malde\u00a0S, Netsch\u00a0C, Rieken\u00a0M, Sakalis\u00a0V, Tutolo\u00a0M (2023) Management of Non-neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO). EAU Guidelines, Edn. presented at the EAU Annual Congress Milan March 2023\u00a0edn. ISBN 978-94-92671-19\u20116.","edition":"Edn. presented"},{"issue":"8","key":"2784_CR9","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s15006-024-3816-4","volume":"166","author":"A Tamalunas","year":"2024","unstructured":"Tamalunas\u00a0A et\u00a0al (2024) Medical treatment of non-neurogenic male LUTS. MMW Fortschr Med 166(8):40\u201343","journal-title":"MMW Fortschr Med"},{"key":"2784_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2022.120931","volume":"308","author":"A Tamalunas","year":"2022","unstructured":"Tamalunas\u00a0A et\u00a0al (2022) Permixon(R), hexane-extracted Serenoa repens, inhibits human prostate and bladder smooth muscle contraction and exerts growth-related functions in human prostate stromal cells. Life Sci 308:120931","journal-title":"Life Sci"},{"issue":"1","key":"2784_CR11","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1097\/MOU.0b013e3282f0d5c8","volume":"18","author":"S Madersbacher","year":"2008","unstructured":"Madersbacher\u00a0S et\u00a0al (2008) Plant extracts: sense or nonsense? Curr Opin Urol 18(1):16\u201320","journal-title":"Curr Opin Urol"},{"issue":"5","key":"2784_CR12","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.euf.2016.04.002","volume":"2","author":"G Novara","year":"2016","unstructured":"Novara\u00a0G et\u00a0al (2016) Efficacy and Safety of Hexanic Lipidosterolic Extract of Serenoa repens (Permixon) in the Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: Systematic Review and Meta-analysis of Randomized Controlled Trials. Eur Urol Focus 2(5):553\u2013561","journal-title":"Eur Urol Focus"},{"issue":"6","key":"2784_CR13","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1111\/bju.14362","volume":"122","author":"R Vela-Navarrete","year":"2018","unstructured":"Vela-Navarrete\u00a0R et\u00a0al (2018) Efficacy and safety of a hexanic extract of Serenoa repens (Permixon((R)) ) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS\/BPH): systematic review and meta-analysis of randomised controlled trials and observational studies. BJU Int 122(6):1049\u20131065","journal-title":"BJU Int"},{"key":"2784_CR14","doi-asserted-by":"crossref","unstructured":"Tacklind, J., et\u00a0al., Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev, 2009(2): p. CD001423.","DOI":"10.1002\/14651858.CD006015.pub2"},{"issue":"11","key":"2784_CR15","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1007\/s00120-009-2141-y","volume":"48","author":"M Oelke","year":"2009","unstructured":"Oelke\u00a0M, Kuczyk\u00a0MA, Herrmann\u00a0TR (2009) Pharmacological treatment of benign prostatic hyperplasia. Urologe A 48(11):1365\u20131375","journal-title":"Urologe A"},{"issue":"2","key":"2784_CR16","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s00120-015-3984-z","volume":"55","author":"K Hofner","year":"2016","unstructured":"Hofner\u00a0K et\u00a0al (2016) S2e guideline of the German urologists: Conservative and pharmacologic treatment of benign prostatic hyperplasia. Urologe A 55(2):184\u2013194","journal-title":"Urologe A"},{"issue":"8","key":"2784_CR17","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1007\/s11255-024-03968-z","volume":"56","author":"L Castur","year":"2024","unstructured":"Castur\u00a0L et\u00a0al (2024) Effect of different alpha-receptor antagonists on metabolic parameters: a head-to-head comparison. Int Urol Nephrol 56(8):2489\u20132494","journal-title":"Int Urol Nephrol"},{"issue":"2","key":"2784_CR18","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.prnil.2023.11.004","volume":"12","author":"A Halawani","year":"2024","unstructured":"Halawani\u00a0A et\u00a0al (2024) Risks and side effects in the medical management of benign prostatic hyperplasia. Prostate Int 12(2):57\u201364","journal-title":"Prostate Int"},{"issue":"1","key":"2784_CR19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s00345-009-0493-y","volume":"28","author":"S Gravas","year":"2010","unstructured":"Gravas\u00a0S, Oelke\u00a0M (2010) Current status of 5alpha-reductase inhibitors in the management of lower urinary tract symptoms and BPH. World J Urol 28(1):9\u201315","journal-title":"World J Urol"},{"issue":"2","key":"2784_CR20","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.eururo.2023.04.008","volume":"84","author":"S Gravas","year":"2023","unstructured":"Gravas\u00a0S et\u00a0al (2023) Summary Paper on the 2023 European Association of Urology Guidelines on the Management of Non-neurogenic Male Lower Urinary Tract Symptoms. Eur Urol 84(2):207\u2013222","journal-title":"Eur Urol"},{"issue":"6","key":"2784_CR21","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1002\/phar.1243","volume":"33","author":"MA Cantrell","year":"2013","unstructured":"Cantrell\u00a0MA, Baye\u00a0J, Vouri\u00a0SM (2013) Tadalafil: a phosphodiesterase\u20115 inhibitor for benign prostatic hyperplasia. Pharmacotherapy 33(6):639\u2013649","journal-title":"Pharmacotherapy"},{"issue":"5","key":"2784_CR22","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.eururo.2012.01.013","volume":"61","author":"M Oelke","year":"2012","unstructured":"Oelke\u00a0M et\u00a0al (2012) Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol 61(5):917\u2013925","journal-title":"Eur Urol"},{"issue":"5","key":"2784_CR23","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.eururo.2012.02.033","volume":"61","author":"M Gacci","year":"2012","unstructured":"Gacci\u00a0M et\u00a0al (2012) A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with alpha-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 61(5):994\u20131003","journal-title":"Eur Urol"},{"issue":"4","key":"2784_CR24","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s00120-011-2522-x","volume":"50","author":"T Bschleipfer","year":"2011","unstructured":"Bschleipfer\u00a0T, Wagenlehner\u00a0F, Weidner\u00a0W (2011) Etiology and pathogenesis of overactive bladder. Urologe A 50(4):477\u2013480","journal-title":"Urologe A"},{"key":"2784_CR25","doi-asserted-by":"crossref","unstructured":"Andersson, K.E., Detrusor contraction--Focus on muscarinic receptors. Scand J Urol Nephrol Suppl, 2004(215): p.\u00a054\u20137.","DOI":"10.1080\/03008880410015192"},{"issue":"19","key":"2784_CR26","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1001\/jama.296.19.2319","volume":"296","author":"SA Kaplan","year":"2006","unstructured":"Kaplan\u00a0SA et\u00a0al (2006) Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 296(19):2319\u20132328","journal-title":"JAMA"},{"issue":"6 Suppl","key":"2784_CR27","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1002\/nau.20500","volume":"26","author":"KE Andersson","year":"2007","unstructured":"Andersson\u00a0KE (2007) LUTS treatment: future treatment options. Neurourol Urodyn 26(6 Suppl):934\u2013947","journal-title":"Neurourol Urodyn"},{"issue":"8","key":"2784_CR28","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1007\/s00120-012-2943-1","volume":"51","author":"F Strittmatter","year":"2012","unstructured":"Strittmatter\u00a0F et\u00a0al (2012) Medical therapy of lower urinary tract symptoms [corrected]. Urologe A 51(8):1125\u20131136","journal-title":"Urologe A"},{"issue":"6","key":"2784_CR29","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/bju.12773","volume":"113","author":"C Chapple","year":"2014","unstructured":"Chapple\u00a0C (2014) Mirabegron the first beta3-adrenoceptor agonist for overactive bladder (OAB): a summary of the phase III studies. BJU Int 113(6):847\u2013848","journal-title":"BJU Int"},{"issue":"1","key":"2784_CR30","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/nau.22505","volume":"33","author":"CR Chapple","year":"2014","unstructured":"Chapple\u00a0CR et\u00a0al (2014) Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability. Neurourol Urodyn 33(1):17\u201330","journal-title":"Neurourol Urodyn"},{"issue":"10","key":"2784_CR31","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1111\/iju.12568","volume":"21","author":"CR Chapple","year":"2014","unstructured":"Chapple\u00a0CR et\u00a0al (2014) Mirabegron 50\u202fmg once-daily for the treatment of symptoms of overactive bladder: an overview of efficacy and tolerability over 12\u00a0weeks and 1\u00a0year. Int J Urol 21(10):960\u2013967","journal-title":"Int J Urol"},{"issue":"2","key":"2784_CR32","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1097\/JU.0000000000000807","volume":"204","author":"D Staskin","year":"2020","unstructured":"Staskin\u00a0D, Frankel\u00a0J, Varano\u00a0S, Shortino\u00a0D, Jankowich\u00a0R, Mudd\u00a0PN Jr (2020) International Phase III, Randomized, Double-Blind, Placebo and Active Controlled Study to Evaluate the Safety and Efficacy of Vibegron in Patients with Symptoms of Overactive Bladder: EMPOWUR. J\u00a0Urol 204(2):316\u2013324. https:\/\/doi.org\/10.1097\/JU.0000000000000807","journal-title":"J Urol"},{"issue":"5","key":"2784_CR33","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1097\/JU.0000000000001574","volume":"205","author":"D Staskin","year":"2021","unstructured":"Staskin\u00a0D, Frankel\u00a0J, Varano\u00a0S, Shortino\u00a0D, Jankowich\u00a0R, Mudd\u00a0PN Jr (2021) Once-Daily Vibegron 75\u202fmg for Overactive Bladder: Long-Term Safety and Efficacy from a\u00a0Double-Blind Extension Study of the International Phase\u00a03 Trial (EMPOWUR). J\u00a0Urol 205(5):1421\u20131429. https:\/\/doi.org\/10.1097\/JU.0000000000001574","journal-title":"J Urol"},{"key":"2784_CR34","unstructured":"Deutsche Gesellschaft f\u00fcr Urologie e.\u202fV. S2e-Leitlinie Diagnostik und Therapie des Benignen Prostatasyndroms (BPS) [Registernummer: 043-034; Langversion 5.0. - Stand Februar 2023]; 2023"},{"key":"2784_CR35","doi-asserted-by":"publisher","first-page":"E200","DOI":"10.25011\/cim.v40i5.28625","volume":"40","author":"D Kang","year":"2017","unstructured":"Kang\u00a0D, Hu\u00a0C, Fu\u00a0Y et\u00a0al (2017) Combination of \u03b1\u2011blocker and 5\u03b1-reductase inhibitor for treatment of benign prostatic hyperplasia. Clin Invest Med 40:E200\u2013E210. https:\/\/doi.org\/10.25011\/cim.v40i5.28625","journal-title":"Clin Invest Med"},{"key":"2784_CR36","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.eururo.2013.03.031","volume":"64","author":"P van Kerrebroeck","year":"2013","unstructured":"van Kerrebroeck\u00a0P, Haab\u00a0F, Angulo\u00a0JC et\u00a0al (2013) Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). Eur Urol Oncol 64:398\u2013407. https:\/\/doi.org\/10.1016\/j.eururo.2013.03.031","journal-title":"Eur Urol"},{"key":"2784_CR37","volume-title":"EAU Guidelines on Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS)","author":"JN Cornu","year":"2024","unstructured":"Cornu\u00a0JN, Gacci\u00a0M, Hashim\u00a0H, Herrmann\u00a0TRW, Malde\u00a0S, Netsch\u00a0C, De Nunzio\u00a0C, Rieken\u00a0M, Sakalis\u00a0V, Tutolo\u00a0M (2024) EAU Guidelines on Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS). European Association of Urology"},{"key":"2784_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0169248","volume":"12","author":"HJ Kim","year":"2017","unstructured":"Kim\u00a0HJ, Sun\u00a0HY, Choi\u00a0H et\u00a0al (2017) Efficacy and Safety of Initial Combination Treatment of an Alpha Blocker with an Anticholinergic Medication in Benign Prostatic Hyperplasia Patients with Lower Urinary Tract Symptoms: Updated Meta-Analysis. PLoS One 12:e0169248. https:\/\/doi.org\/10.1371\/journal.pone.0169248","journal-title":"PLoS One"},{"key":"2784_CR39","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.urology.2013.10.034","volume":"83","author":"N Hao","year":"2014","unstructured":"Hao\u00a0N, Tian\u00a0Y, Liu\u00a0W et\u00a0al (2014) Antimuscarinics and \u03b1\u2011blockers or \u03b1\u2011blockers monotherapy on lower urinary tract symptoms--a meta-analysis. Urol Video J 83:556\u2013562. https:\/\/doi.org\/10.1016\/j.urology.2013.10.034","journal-title":"Urology"},{"key":"2784_CR40","doi-asserted-by":"publisher","first-page":"13","DOI":"10.23736\/S0393-2249.19.03408-8","volume":"72","author":"Y Sun","year":"2020","unstructured":"Sun\u00a0Y, Peng\u00a0B, Lei\u00a0GL et\u00a0al (2020) Study of phosphodiesterase 5 inhibitors and \u03b1\u2011adrenoceptor antagonists used alone or in combination for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Minerva Urol Nefrol 72:13\u201321. https:\/\/doi.org\/10.23736\/S0393-2249.19.03408-8","journal-title":"Minerva Urol Nefrol"},{"key":"2784_CR41","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.euf.2019.05.007","volume":"6","author":"P Kallidonis","year":"2020","unstructured":"Kallidonis\u00a0P, Adamou\u00a0C, Kotsiris\u00a0D et\u00a0al (2020) Combination Therapy with Alpha-blocker and Phosphodiesterase\u20115 Inhibitor for Improving Lower Urinary Tract Symptoms and Erectile Dysfunction in Comparison with Monotherapy: A Systematic Review and Meta-analysis. Eur Urol Oncol 6:537\u2013558. https:\/\/doi.org\/10.1016\/j.euf.2019.05.007","journal-title":"Eur Urol Focus"},{"key":"2784_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.763184","volume":"13","author":"Z Fan","year":"2022","unstructured":"Fan\u00a0Z, Shi\u00a0H, Zhang\u00a0J et\u00a0al (2022) Comparative Efficacy of Different Drugs for Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia: A Bayesian Network Meta-Analysis. Front Pharmacol 13:763184. https:\/\/doi.org\/10.3389\/fphar.2022.763184","journal-title":"Front Pharmacol"},{"key":"2784_CR43","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s15006-024-3816-4","volume":"166","author":"A Tamalunas","year":"2024","unstructured":"Tamalunas\u00a0A, Keller\u00a0P, G\u00f6tz\u00a0M et\u00a0al (2024) Medikament\u00f6se Therapie bei Symptomen des unteren Harntrakts. MMW Fortschr Med 166:40\u201343. https:\/\/doi.org\/10.1007\/s15006-024-3816-4","journal-title":"MMW Fortschr Med"},{"key":"2784_CR44","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.juro.2013.09.059","volume":"191","author":"A Casab\u00e9","year":"2014","unstructured":"Casab\u00e9\u00a0A, Roehrborn\u00a0CG, Da Pozzo\u00a0LF et\u00a0al (2014) Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia. J\u00a0Urol 191:727\u2013733. https:\/\/doi.org\/10.1016\/j.juro.2013.09.059","journal-title":"J Urol"},{"key":"2784_CR45","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010060.pub2","volume":"11","author":"S Pattanaik","year":"2018","unstructured":"Pattanaik\u00a0S, Mavuduru\u00a0RS, Panda\u00a0A et\u00a0al (2018) Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia. Cochrane Database Syst Rev 11:CD010060. https:\/\/doi.org\/10.1002\/14651858.CD010060.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"2784_CR46","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.euf.2019.10.019","volume":"6","author":"H Kakizaki","year":"2020","unstructured":"Kakizaki\u00a0H, Lee\u00a0KS, Yamamoto\u00a0O et\u00a0al (2020) Mirabegron Add-on Therapy to Tamsulosin for the Treatment of Overactive Bladder in Men with Lower Urinary Tract Symptoms: A Randomized, Placebo-controlled Study (MATCH). Eur Urol Oncol 6:729\u2013737. https:\/\/doi.org\/10.1016\/j.euf.2019.10.019","journal-title":"Eur Urol Focus"},{"key":"2784_CR47","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1097\/JU.0000000000000738","volume":"203","author":"SA Kaplan","year":"2020","unstructured":"Kaplan\u00a0SA, Herschorn\u00a0S, McVary\u00a0KT et\u00a0al (2020) Efficacy and Safety of Mirabegron versus Placebo Add-On Therapy in Men with Overactive Bladder Symptoms Receiving Tamsulosin for Underlying Benign Prostatic Hyperplasia: A Randomized, Phase 4 Study (PLUS). J\u00a0Urol 203:1163\u20131171. https:\/\/doi.org\/10.1097\/JU.0000000000000738","journal-title":"J Urol"},{"key":"2784_CR48","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.eururo.2012.02.036","volume":"62","author":"P Madhuvrata","year":"2012","unstructured":"Madhuvrata\u00a0P, Singh\u00a0M, Hasafa\u00a0Z et\u00a0al (2012) Anticholinergic drugs for adult neurogenic detrusor overactivity: a systematic review and meta-analysis. Eur Urol Oncol 62:816\u2013830. https:\/\/doi.org\/10.1016\/j.eururo.2012.02.036","journal-title":"Eur Urol"},{"key":"2784_CR49","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1002\/nau.23566","volume":"37","author":"J Krhut","year":"2018","unstructured":"Krhut\u00a0J, Borovi\u010dka\u00a0V, B\u00edlkov\u00e1\u00a0K et\u00a0al (2018) Efficacy and safety of mirabegron for the treatment of neurogenic detrusor overactivity-Prospective, randomized, double-blind, placebo-controlled study. Neurourol Urodyn 37:2226\u20132233. https:\/\/doi.org\/10.1002\/nau.23566","journal-title":"Neurourol Urodyn"},{"key":"2784_CR50","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1055\/s-0043-1770093","volume":"45","author":"LGF Sartori","year":"2023","unstructured":"Sartori\u00a0LGF, Nunes\u00a0BM, Farah\u00a0D et\u00a0al (2023) Mirabegron e anticolin\u00e9rgicos no tratamento da s\u00edndrome da bexiga hiperativa: metan\u00e1lise. Synfacts 45:337\u2013346. https:\/\/doi.org\/10.1055\/s-0043-1770093","journal-title":"Rev Bras Ginecol Obstet"}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-026-02784-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-026-02784-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-026-02784-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T13:18:16Z","timestamp":1774876696000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-026-02784-w"}},"subtitle":["Medikamente, Neuheiten und Ausblicke","Medications, innovations and future prospects"],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["2784"],"URL":"https:\/\/doi.org\/10.1007\/s00120-026-02784-w","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"value":"2731-7064","type":"print"},{"value":"2731-7072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"15 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"P.\u00a0Keller:\n                      A.\u00a0Finanzielle Interessen: P.\u00a0Keller gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Funktionsoberarzt, LMU-Klinikum, Urologie.\n                      A.\u00a0Tamalunas:\n                      A.\u00a0Finanzielle Interessen: Forschungsunterst\u00fctzung: Apogepha Arzneimittel GmbH.\u00a0\u2013 Vortragshonorare, Advisory Board: Pfizer; Vortragshonorare, Advisory Board: MSD\/Merck; Vortragshonorare, Kostenerstattung: Apogepha; Kostenerstattung: Pierre Fabre.\u00a0\u2013 Beratung: Trovagene, Cardiff Oncology, Apogepha.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Angestellter Facharzt f\u00fcr Urologie, Urologische Klinik, LMU-Klinikum, Ludwig-Maximilians-Universit\u00e4t, M\u00fcnchen\u00a0| Mitgliedschaften: Arbeitskreis Benignes Prostatasyndrom (AKBPS), Deutsche Gesellschaft f\u00fcr Urologie (DGU), European Association of Urology (EAU), European Society of Medical Oncology.\n                      M.\u00a0Atzler:\n                      A.\u00a0Finanzielle Interessen: M.\u00a0Atzler gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Assistenzarzt Urologie, Klinikum Gro\u00dfhadern, LMU, M\u00fcnchen.\n                      M.\u00a0Kidess:\n                      A.\u00a0Finanzielle Interessen: M.\u00a0Kidess gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Assistenzarzt Urologie, Klinikum der Universit\u00e4t M\u00fcnchen, Campus Gro\u00dfhadern\u00a0| Mitgliedschaften: DGU, GeSRU.\n                      L.\u00a0Stadelmeier:\n                      A.\u00a0Finanzielle Interessen: L.\u00a0Stadelmeier gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Assistenzarzt, Urologische Klinik und Poliklinik, LMU-Klinikum, M\u00fcnchen.\n                      N.\u00a0Pyrgidis:\n                      A.\u00a0Finanzielle Interessen: N.\u00a0Pyrgidis gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Angestellter Urologe, LMU, Urologische Klinik und Poliklinik.\n                      M.\u00a0Hennenberg:\n                      A.\u00a0Finanzielle Interessen: Deutsche Forschungsgemeinschaft (DFG), Einzelf\u00f6rderungen (HE 5925\/11\u20111, HE 5925\/9\u20111, HE 5825\/8\u20111, HE 5825\/6-1); Horst-J\u00fcrgen-L\u00fchl-Stiftung (2022).\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Biologe, Univ.-Prof., LMU M\u00fcnchen bzw. Urologische Klinik und Poliklinik, LMU-Klinikum, LMU M\u00fcnchen\u00a0| Mitgliedschaft: Deutscher Hochschulverband (DHV).\n                      C.G.\u00a0Stief:\n                      A.\u00a0Finanzielle Interessen: C.G. Stief gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Direktor der Urologischen Klinik und Poliklinik, LMU-Klinikum, M\u00fcnchen.\n                      P.\u00a0Weinhold:\n                      A.\u00a0Finanzielle Interessen: P.\u00a0Weinhold gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Leitender Oberarzt, Leitung Prostatazentrum\u00a0| LMU-Klinikum, M\u00fcnchen.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autorinnen und Autoren."}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf\n                      \n                      .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}